Last Updated : October 16, 2023
Details
Generic Name:
treosulfan
Project Status:
Not filed
Therapeutic Area:
Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (pediatric)
Manufacturer:
Medexus Pharmaceuticals Inc.
Brand Name:
Trecondyv
Project Line:
Reimbursement Review
Project Number:
N/A
Manufacturer Requested Reimbursement Criteria1:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Submission Type:
Non Submission
Indications:
In combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation in pediatric patients older than 1 year old with AML or MDS.
Recommendation Type:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : October 16, 2023